We are studying how to better care for people who come to the emergency room with chest pain. Right now, doctors use a tool called the HEART score to decide how serious the chest pain is and what tests the patient might need. But for patients who are in the "middle risk" group, it's hard to tell if they really need more heart tests or not. This can lead to too many tests and overcrowding in the hospital. Our study looks at new ways to help doctors decide which of these patients actually need more testing, so they can give the right care more quickly and avoid unnecessary delays or tests.

We are interviewing primary care providers to get their thoughts on how best to provide care to patients with eating disorders.

We investigate how reports from election observation missions (EOMs) shape perceptions of election integrity. We also investigate the effect of government criticism of EOMs.

The purpose of this IRB approved Humanitarian Use of a device is to allow patients to be treated with LDL-Apheresis, using the LIPOSORBER® LA-15 system. This device is approved for adult and pediatric patients with Focal Segmental Glomeruloslerosis as a Humanitarian Use Device. Its effectiveness has not been demonstrated.

To widen the availability of obstetric ultrasound through technology

The purpose of this research study is to understand how the management of Patient Reported Outcomes (PROs) could help improve surgical care for patients undergoing chest surgeries. PROs are symptoms directly reported by patients through the completion of a survey.

Speak with Medicaid providers about the upcoming change to how providers are reimbursed for services

The purpose of this study is to evaluate both sporadic (not inherited), and familial (inherited), forms of frontotemporal lobar degeneration (FTLD). Patients include both those who have symptoms of FTLD and those who do not (yet have a family history involving FTLD). This is an observational study, meaning that there is no investigational treatment involved. We will be working with patients for up to a 5 year period to learn more about FTLD using a neurological exam, tests of memory, behavior, and judgement, MRI, and biospecimen collection (blood and/or CSF). This study involves genetic testing of the genes so far identified to be associated with FTLD. The overall goal is to help better understand FTLD, to better understand the genetics of FTLD, and to use the information we learn to guide improved patient care and potential drug development.

The purpose of this study is to measure the effect of 30 mg RE104 on adjustment disorder symptoms (depressed mood or anxiety) compared to 1.5 mg RE104 in participants with cancer or other illnesses in order to decrease these symptoms.

INDUCTION: To evaluate the efficacy of icotrokinra versus placebo in inducing clinical remission MAINTENANCE: To evaluate the efficacy of a maintenance regimen of icotrokinra versus placebo in achieving clinical remission in participants with moderately to severely active UC who were induced into clinical response with icotrokinra